anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Tretinoin
Trial phase: Phase 4
ATC code: D10AD01 | D10AD04 | D10AD51 | D10AD54 | D10BA01 | D11AH04 | L01XF01 | L01XF02
SMILES: CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Altreno 0.05% lotion: Acne patients will be assigned to Altreno once daily.
Eligibility criteria:
Inclusion Criteria:

A confirmed diagnosis of acne that warrants initiating topical medications.
Denies use of any prescribed systemic acne treatments in the past 30 days.
Denies use of any prescribed topical medications in the past 30 days.
Denies use of any OTC topical acne medications in the past 14 days.
Denies use of any emollients in the past 24 hours (if feasible).
Denies bathing or facial washing in the past 12 hours (if feasible).
Willingness to adhere to the recommended topical regimen during the duration of the study.

Exclusion Criteria:

Women who are pregnant, breastfeeding, or planning to get pregnant during the study.
Use of any investigational drug(s) in the past 3 months.
Intervention: Fentanyl
Trial phase: Phase 4
ATC code: N01AH01 | N01AH51 | N02AB03
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia

Fentanyl: 50 µg fentanyl
Eligibility criteria:
Inclusion Criteria:

Adults aged 18 years or older;
Scheduled for elective knee arthroscopy without anticipated ligamentous repair;
Planned general anesthesia without a regional block or wound infiltration with local anesthesia;
Planned day-of-surgery discharge.

Exclusion Criteria:

Opioid tolerance defined by ≥15 mg of oral morphine daily or equianalgesic dose of another opioid within 30 days of surgery;
Known hypersensitivity to sufentanil or components of DSUVIA;
Patients with an allergy or hypersensitivity to opioids;
Pregnancy or actively breastfeeding;
Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug;
Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection.
Intervention: Naropin
Trial phase: Phase 4
SMILES: CCC[NH+]1CCCCC1C(=O)Nc1c(C)cccc1C.O.[Cl-]
Sex: All
Age groups: Child
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: All enrolled patients will have bilateral erector spinae blocks (with catheters for postoperative local anesthetic infusion) placed by the by a member of the clinical regional anesthesia team (under the supervision of a member of the research team) in a sterile fashion after the cardiac surgical procedure is completed. Postoperative continuous infusion of local anesthetic (ropivacaine) via the nerve block catheter is initiated and managed by the Acute Pain Service (per standardized, clinical weight-based protocols).

Bilateral erector spinae blocks using ropivacaine: Bilateral chest wall nerve blocks using ropivacaine.
Eligibility criteria:
Inclusion Criteria:

Scheduled as part of the cardiac surgical ERAS program: Patients scheduled for elective surgeries for the following congenital anomalies, or similar: atrial septal defects (all types), partial anomalous pulmonary venous connection (non-obstructed), cor-triatriatum, VSD, partial AV canal, sub-aortic membrane resection, anomalous aortic origin of the coronary arteries, and pulmonary valve/conduit implantation
Scheduled for a primary sternotomy.
Ages 2 years through 17 years.

Exclusion Criteria:

Single ventricle physiology.
Significant scoliosis or other anatomic contraindications to ESB.
Significant intraoperative hemodynamic instability or bleeding, as ascertained by clinicians taking care of the patient.
Patients with severe neurodevelopmental delays.
Patients with previous chronic pain syndromes.
Patients with a history of greater than 24 hours of postoperative or post-procedural opioid treatment at any point in the 2 months prior to surgery.
Lack of parental consent and/or child assent.
Intervention: Tretinoin
Trial phase: Phase 1 | Phase 2
ATC code: D10AD01 | D10AD04 | D10AD51 | D10AD54 | D10BA01 | D11AH04 | L01XF01 | L01XF02
SMILES: CC(C=CC1=C(C)CCCC1(C)C)=CC=CC(C)=CC(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Isotretinoin: Participants will be getting isotretinoin (1-1.5 mg/kg/week)
Eligibility criteria:
Inclusion Criteria:

All patients 12 years and older with the diagnosis of moderate acne vulgaris

Exclusion Criteria:

Patients who are at baseline on long-term tetracycline antibiotics, long-term trimethoprim-sulfamethoxazole, or on spironolactone for any reason
Patients who have taken isotretinoin in the past 6 months
Patients with hypersensitivity to isotretinoin or to any of its components
Females who are pregnant, likely to become pregnant, or will be breast-feeding during the study period
Patients with a history of major depression, mania, or psychosis with an active episode during the past year including current psychotic symptoms and/or current suicidal ideation
Adult patients with cognitive impairment
Patients with baseline kidney or liver disease
Patients with baseline hypertriglyceridemia
Patients with history of or current pseudotumor cerebri
Patients with any clinically significant unstable medical condition which could pose a risk to the safety of the patient
Inability or unwillingness of subject or legal guardian/representative to give informed consent
Intervention: Sirolimus
Trial phase: Early Phase 1
ATC code: L01EG04 | L04AA10 | S01XA23
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: All
Age groups: Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 22
Group description: Ointment is applied to a color coded area on the subject forearm daily.

Rapamycin Topical Ointment: 8% topical rapamycin ointment
Eligibility criteria:
Inclusion Criteria:

65-95 years of age.
Good health with all chronic diseases (hypertension, coronary artery disease, etc.) clinically stable.
Selected subjects will be in good health (Per the World Health Organization, good health will be defined as complete physical, mental, and social well-being and not merely the absence of disease or infirmity).
All diseases or infirmities will be clinically stable whether managed by medications or not.
CLOX score of 10 or greater
Women will be postmenopausal
Postmenopausal women taking hormone replacement will be included if they have been on a stable dose for ≥6 months
Live within a 20 mile drive of the UTHSA campus (7703 Floyd Curl Drive, San Antonio, TX)

Exclusion Criteria:

Diabetes.
History of skin ulcers or poor wound healing, or keloid formers.
Smoking.
Liver disease.
Coumadin anti-coagulation.
Treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin, etc. - due to role in rapamycin metabolism).
Treatment with an immunosuppressant (prednisone, etc.) within 6 months.
History of recent (within 6 months) Myocardial Infarction or active Coronary Disease.
Hypersensitivity to rapamycin or petrolatum (ointment vehicle)
Arm tattoos or scars in application area
Intervention: Methadone
Trial phase: Phase 3
ATC code: N02AC52 | N07BC02
SMILES: CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 113
Group description: A 75 mg REL-1017 loading dose (three 25 mg REL-1017 tablets) will be administered on Day-1 of the 28-day treatment period. From Day-2 to Day-28, participants will take 25 mg REL-1017 in addition to their ongoing antidepressant.

REL-1017: REL-1017 tablet
Eligibility criteria:
Inclusion Criteria:

Adults 18 to 65 years, inclusive.
Diagnosed with Major Depressive Disorder (MDD) based on structured clinical interview for Diagnostic and Statistical Manual of Mental Disorders, DSM-5 (SCID-5) for MDD.
Current major depressive episode.
With inadequate response to 1-3 first-line antidepressants administered at an adequate and stable dose

Exclusion Criteria:

Any current and primary psychiatric disorder other than Major Depressive Disorder.
Severe alcohol or substance use disorder.
History of bipolar I and II disorder, psychosis, and/or mania.
Acute or chronic condition that, in the Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.
Prior participation in a ketamine, esketamine, dextromethorphan or any other NMDAR- antagonist study, or received esketamine at any time.
Intervention: Theanine
Trial phase: Early Phase 1
SMILES: CCNC(=O)CC[C@H](N)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.
Eligibility criteria:
Inclusion Criteria:

Adult, aged between 18 and 65 years old;
Able to read/speak English and give informed consent
No current or history of Axis I psychiatric disorders by DSM-5.
Free of psychotropic medication use

Exclusion Criteria:

History of significant acute or chronic neurological or medical disorder or condition that increases risk for seizure with TMS;
History of alcohol use disorder, nicotine dependence, adjustment disorder;
History of allergic reactions to L-theanine or green tea;
Pregnancy;
Unable/unwilling to abstain from nutraceutical supplements and psychotropic agents during participation in the study
Unable/ unwillingness to refrain from recreational substance use (e.g. alcohol or marijuana) during participation in the study;
Meet criteria for exclusion from TMS or MRI procedures, including intracranial metal implants or nonremovable ferromagnetic items in the head/neck.
Intervention: Betaxolol
Trial phase: Phase 4
ATC code: C07AB05 | S01ED02 | S01ED52
SMILES: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: This arm will follow an ABAB sequence. "A" representing ON beta blockers and "B" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.

Beta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On [A] vs Off [B]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.

Subjects will be randomized into either ABAB or BABA sequences.
Eligibility criteria:
Inclusion Criteria:

Ambulatory adults ≥65 years of age with Heart Failure with Preserved Ejection Fraction (HFpEF) according to ACC/AHA guidelines: (signs and symptoms of Heart failure [HF] and ejection fraction [EF] ≥50%)
Taking Beta blocker

Exclusion Criteria:

Alternate Causes of HFpEF Syndrome:

Severe valvular disease
Constrictive pericarditis
High output heart failure
Infiltrative cardiomyopathy

Other compelling indication for beta blocker:

Prior EF < 50%
Hypertrophic cardiomyopathy
Angina symptoms
Acute coronary syndrome, myocardial infarction or coronary artery bypass surgery in prior 3 year
History of ventricular tachycardia
Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year
Sinus tachycardia > 100 beats per minute (bpm), atrial arrhythmia with ventricular rate >90 bpm, systolic blood pressure > 160 mmHg

Clinical instability (N-of-1 trials are appropriate for stable conditions only)

Decompensated HF
Hospitalized in past 30 days
Medication changes or procedures in prior 14 days (to prevent confounding from other interventions), at PI discretion
Estimated life expectancy <6 months
Moderate-severe dementia or psychiatric disorder precluding informed consent
Any condition that, in Principal Investigator's opinion, makes the patient unsuitable for study participation
Intervention: Betaxolol
Trial phase: Phase 4
ATC code: C07AB05 | S01ED02 | S01ED52
SMILES: CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: This arm will follow a BABA sequence. "A" representing ON beta blockers and "B" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.

Beta blockers: The intervention is a two-arm crossover withdrawal/ reversal design (On [A] vs Off [B]) with up to 4 periods, each period lasting up to 6 weeks. During the On period (A), subjects will be on their beta blocker. During the Off period (B), their beta blockers will be down-titrated and subsequently discontinued.

Subjects will be randomized into either ABAB or BABA sequences.
Eligibility criteria:
Inclusion Criteria:

Ambulatory adults ≥65 years of age with Heart Failure with Preserved Ejection Fraction (HFpEF) according to ACC/AHA guidelines: (signs and symptoms of Heart failure [HF] and ejection fraction [EF] ≥50%)
Taking Beta blocker

Exclusion Criteria:

Alternate Causes of HFpEF Syndrome:

Severe valvular disease
Constrictive pericarditis
High output heart failure
Infiltrative cardiomyopathy

Other compelling indication for beta blocker:

Prior EF < 50%
Hypertrophic cardiomyopathy
Angina symptoms
Acute coronary syndrome, myocardial infarction or coronary artery bypass surgery in prior 3 year
History of ventricular tachycardia
Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year
Sinus tachycardia > 100 beats per minute (bpm), atrial arrhythmia with ventricular rate >90 bpm, systolic blood pressure > 160 mmHg

Clinical instability (N-of-1 trials are appropriate for stable conditions only)

Decompensated HF
Hospitalized in past 30 days
Medication changes or procedures in prior 14 days (to prevent confounding from other interventions), at PI discretion
Estimated life expectancy <6 months
Moderate-severe dementia or psychiatric disorder precluding informed consent
Any condition that, in Principal Investigator's opinion, makes the patient unsuitable for study participation
Intervention: Fisetin
Trial phase: Phase 2
SMILES: O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Subjects who received treatment drug Fisetin

Fisetin: ~20mg/kg /day oral for four days (days 0,1 and days 8,9)
Eligibility criteria:
Inclusion Criteria:

Males and females, at least 18 years of age, capable and willing to provide informed consent;
Patient must have received a diagnosis of COVID-19 infection within the last 3 days;
Outpatient setting (not currently hospitalized);
Patient must possess at least one of the following high-risk criteria: 60 years or more of age, obesity (BMI ≥ 30 kg/m2), diabetes mellitus, uncontrolled hypertension (systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma, chronic obstructive pulmonary disease, or present or past smoking), known heart failure, known coronary disease, fever of ≥38.4°C within the last 48 hours, dyspnea at the time of presentation, the combination of high neutrophil count and low lymphocyte count;
Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion;
Patient or their caregiver must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria:

Patient currently hospitalized or under immediate consideration for hospitalization;
Patient currently in shock or with hemodynamic instability;
Patient with severe hepatic disease (as per clinical judgement) and liver enzymes >10x the upper limit of normal;
Female patient who is pregnant, breast-feeding, or is considering becoming pregnant during the study or for 1 day after the last dose of study medication;
Patient currently taking Sirolimus, Tacrolimus, or other mTOR inhibitors for other indications (mainly chronic indications represented by organ transplantation or autoimmune diseases);
On Warfarin therapy;
Patient with a history of an allergic reaction or significant sensitivity to Fisetin;
Patient undergoing chemotherapy for cancer;
Patient is considered by the investigator, for any reason, to be an unsuitable study candidate.
Intervention: Fentanyl
Trial phase: Phase 4
ATC code: N01AH01 | N01AH51 | N02AB03
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 110
Group description: Participant will receive 2mg IV midazolam and 0.5-1mcg/kg IV fentanyl over 2 minutes, which can be repeated q5m until appropriate analgesia is achieved.

Fentanyl: IV fentanyl
Eligibility criteria:
Inclusion Criteria:

Aged 14 years or older
Voluntarily requesting surgical pregnancy termination
Intrauterine pregnancy up to 13 weeks 6 days by transabdominal or transvaginal ultrasound performed on day of procedure
Eligible for suction curettage
English or Spanish speaking
Able and willing to give informed consent and agree to terms of the study

Exclusion Criteria:

Age less than 14 years
Reaspiration procedure or failed medication abortion
Early pregnancy loss
Alcohol use disorder or acute alcohol intoxication
Currently incarcerated
Gestational age 14 weeks or more
Requesting a specific pain regimen
Premedication with misoprostol
Contraindications or allergies to ketamine or fentanyl
Intervention: Acetaminophen
Trial phase: Phase 4
ATC code: N02AJ01 | N02AJ06 | N02AJ13 | N02AJ17 | N02BE01 | N02BE51 | N02BE71
SMILES: CC(=O)Nc1ccc(O)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 30
Group description: Standard of care- weight based dose of liquid acetaminophen-hydrocodone- 0.15 mg/kg/dose every six hours with a max dose of 10 mg/dose

Acetaminophen-Hydrocodone: Narcotic
Eligibility criteria:
Inclusion Criteria:

isolated supracondylar humerus fracture
undergoing closed reduction with percutaneous pinning (CRPP)

Exclusion Criteria:

Allergies to acetaminophen, ibuprofen, and/or acetaminophen-HYDROcodone
Liver or renal disease
history of bleeding disorder
medical diagnosis of juvenile arthritis
on chronic NSAIDs or Opioids PRIOR to the procedure
medical diagnosis of coagulopathies, open fractures, other injuries at time of diagnosis (multi-system trauma)
vascular compromise and/or compartment syndrome upon admission
Intervention: Amiodarone
Trial phase: Phase 4
ATC code: C01BD01
SMILES: CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Initial amiodarone bolus of 150 mg IV over 10 minutes then a 24-hour amiodarone loading infusion (1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours), followed by enteral (400 mg amiodarone oral or per tube three times daily or 2 times daily if the patient has gastrointestinal intolerance when taking the drug three times daily) or intravenous amiodarone (0.5 mg/min continuous infusion) to complete an 8-gm total amiodarone load. Maintenance amiodarone (200 mg amiodarone oral or per tube once daily) at discretion of attending physician.

AMIODARONE: Assess the effectiveness of different dosing strategies of amiodarone.
Eligibility criteria:
Inclusion Criteria:

Subject must be 18 years old or older
Subject must be willing to give written informed consent
Subject must undergo or scheduled for non-emergent cardiac surgery, including coronary artery bypass grafting (CABG), non-infectious valve repair or replacement, atrial or septal defect repair, thoracic aortic replacement surgery, or any combination of these procedures

Exclusion Criteria:

Documented allergy to amiodarone or iodine
History of atrial fibrillation or other heart conduction system abnormality
History of cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system
Scheduled cardiac maze, pulmonary vein isolation, or other procedure affecting the conduction system
Low cardiac index or cardiogenic shock requiring pharmacologic or mechanical support
History of pre-existing respiratory system disease requiring oxygen therapy prior to admission
History of cirrhosis or other chronic liver diseases
Pregnancy or breastfeeding mothers
Prisoner status